Stifel Nicolaus Has Lowered Expectations for Arvinas (NASDAQ:ARVN) Stock Price

Arvinas (NASDAQ:ARVN) had its target price dropped by research analysts at Stifel Nicolaus from $63.00 to $51.00 in a research report issued to clients and investors on Wednesday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Stifel Nicolaus’ price target suggests a potential upside of 188.46% from the company’s previous close.

A number of other research analysts have also commented on ARVN. Stephens initiated coverage on shares of Arvinas in a research report on Monday, November 18th. They set an “overweight” rating and a $55.00 price target for the company. BTIG Research began coverage on Arvinas in a research note on Tuesday, December 10th. They issued a “buy” rating and a $69.00 target price on the stock. BMO Capital Markets cut their price objective on Arvinas from $90.00 to $88.00 and set an “outperform” rating for the company in a report on Wednesday, November 20th. Guggenheim reiterated a “buy” rating on shares of Arvinas in a research report on Thursday, December 12th. Finally, Wedbush reissued an “outperform” rating and issued a $57.00 price target on shares of Arvinas in a report on Tuesday. One equities research analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the stock. According to MarketBeat.com, Arvinas has an average rating of “Moderate Buy” and a consensus target price of $59.91.

Arvinas Stock Performance

Shares of ARVN opened at $17.68 on Wednesday. Arvinas has a 52-week low of $16.61 and a 52-week high of $53.08. The stock’s 50-day simple moving average is $19.33 and its 200 day simple moving average is $23.36. The stock has a market capitalization of $1.21 billion, a price-to-earnings ratio of -3.79 and a beta of 1.88.

Arvinas (NASDAQ:ARVN) last announced its quarterly earnings results on Tuesday, February 11th. The company reported ($0.63) earnings per share for the quarter, beating the consensus estimate of ($1.07) by $0.44. During the same period in the prior year, the firm earned ($2.53) EPS. On average, research analysts forecast that Arvinas will post -3.22 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Arvinas

Institutional investors and hedge funds have recently bought and sold shares of the stock. nVerses Capital LLC bought a new stake in Arvinas in the third quarter valued at approximately $39,000. KBC Group NV increased its stake in shares of Arvinas by 77.0% in the fourth quarter. KBC Group NV now owns 2,885 shares of the company’s stock worth $55,000 after buying an additional 1,255 shares during the period. Mirae Asset Global Investments Co. Ltd. raised its holdings in Arvinas by 21.5% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,483 shares of the company’s stock valued at $61,000 after buying an additional 440 shares during the last quarter. Quantbot Technologies LP boosted its position in Arvinas by 147.3% during the 3rd quarter. Quantbot Technologies LP now owns 4,367 shares of the company’s stock valued at $108,000 after buying an additional 2,601 shares during the period. Finally, Exchange Traded Concepts LLC grew its holdings in Arvinas by 37.0% in the 3rd quarter. Exchange Traded Concepts LLC now owns 6,659 shares of the company’s stock worth $164,000 after acquiring an additional 1,798 shares during the last quarter. 95.19% of the stock is currently owned by institutional investors.

Arvinas Company Profile

Arvinas, Inc, a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. The company engineers proteolysis targeting chimeras (PROTAC) targeted protein degraders that are designed to harness the body’s own natural protein disposal system to degrade and remove disease-causing proteins.